Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Magnesium Supplementation in Addition to Standard Chemo-immunotherapy in Patients With Locally Advanced Unresectable Stage III or Metastatic Stage IV Non-small Cell Lung Cancer (NSCLC). A Double-blind Randomized Multicenter Phase II/III Study.
Swiss Cancer Institute
230 participants
Aug 1, 2026
INTERVENTIONAL
Conditions
Summary
This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes. Magnesium is important for immune function, and low levels during chemotherapy are common. Participants are randomly assigned to receive either magnesium or a placebo, both as infusions and tablets. Neither the participants nor the doctors know who receives which treatment. The study compares the two groups to see if magnesium helps and how well it is tolerated.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
2.5 mmol film-coated tablets in addition to standard first line therapy
4 mmol IV formulation in addition to standard first line therapy
Placebo film-coated tablets corresponding to Magnesiocard in addition to standard first line therapy
Placebo for injection corresponding to Magnesium Diasporal in addition to standard first line therapy
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07149649